Amyloid β-Protein (25-35) amide |
Catalog No.GA20745
One-Click Copy Product Info
|
Amyloid β-Protein (25-35) amide is a product of the amidation of amyloid-β (Aβ), in which the ability to generate Aβ is strongly reduced.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 147490-49-1
Sample solution is provided at 25 µL, 10mM.
Amyloid β-Protein (25-35) amide is a product of the amidation of amyloid-β (Aβ), in which the ability to generate Aβ is strongly reduced[1]. Amyloid β-Protein (25-35) amide is a modified fragment sequence of the Aβ peptide, consisting of amino acids 25-35, with the C-terminus blocked by an amide bond[2]. The amino acid sequence of Aβ (25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents amino acid 25 and the last Met represents amino acid 35[3]. Aβ is neurotoxic, but the strength of the toxicity is not related to its aggregation state. Aβ oligomers also show neurotoxicity and cause neuronal damage[4, 5]. Aβ is involved in the pathogenesis of Alzheimer's disease and is present in neurons of the subiculum and entorhinal cortex of Alzheimer's brain samples and inclusion body myositis (IBM) muscles. It binds to receptors present in microglia and is able to insert into lipid membranes[6].
References:
[1] Li H, Rahimi F, Bitan G. Modulation of amyloid β-protein (Aβ) assembly by homologous C-terminal fragments as a strategy for inhibiting Aβ toxicity[J]. ACS chemical neuroscience, 2016, 7(7): 845-856.
[2] Ghosh N, Kundu L M. Breaker peptides against amyloid-β aggregation: a potential therapeutic strategy for Alzheimer’s disease[J]. Future Medicinal Chemistry, 2021, 13(20): 1767-1794.
[3] Cheung N S, Small D H, Livett B G. An Amyloid Peptide, βA4 25–35, Mimics the Function of Substance P on Modulation of Nicotine‐Evoked Secretion and Desensitization in Cultured Bovine Adrenal Chromaffin Cells[J]. Journal of neurochemistry, 1993, 60(3): 1163-1166.
[4] Aleksis R, Oleskovs F, Jaudzems K, et al. Structural studies of amyloid-β peptides: Unlocking the mechanism of aggregation and the associated toxicity[J]. Biochimie, 2017, 140: 176-192.
[5] Rahimi F, Li H, Sinha S, et al. Modulators of amyloid β-protein (Aβ) self-assembly[M]//Developing Therapeutics for Alzheimer's Disease. Academic Press, 2016: 97-191.
[6] Millucci L, Ghezzi L, Bernardini G, et al. Conformations and biological activities of amyloid beta peptide 25-35[J]. Current Protein and Peptide Science, 2010, 11(1): 54-67.
| Cas No. | 147490-49-1 | SDF | |
| Formula | C45H82N14O13S | M.Wt | 1059.3 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 944 μL | 4.7201 mL | 9.4402 mL |
| 5 mM | 188.8 μL | 944 μL | 1.888 mL |
| 10 mM | 94.4 μL | 472 μL | 944 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)